Psychedelic-Assisted Therapy: What the Evidence Says

This page reflects our understanding of mental health topics as of 2026. If you are reading this at a later date, some details may no longer be current, so please verify anything important against up to date sources. If you notice anything that needs updating, we would welcome you letting us know.

Psychedelic-assisted therapy is a treatment approach that combines a psychedelic or related substance, such as psilocybin, MDMA, or ketamine, with structured psychotherapy before, during, and after the experience. Early clinical trials have shown promising results for treatment-resistant depression, PTSD, and some other conditions, but research is still developing, and results vary between studies. In Canada, psilocybin and MDMA remain controlled substances and are available for therapy only through clinical trials or special approval from Health Canada. Esketamine, a form of ketamine, is approved for treatment-resistant depression. These treatments carry real risks and are not suitable for everyone, so careful medical screening and qualified support are essential.

How Psychedelic-Assisted Therapy Works

Treatment typically has three phases:

Preparation. Several sessions to build trust, discuss intentions, and prepare for the experience.
Dosing session. The substance is taken in a controlled clinical setting, with trained professionals present for the full session, which can last several hours.
Integration. Follow-up therapy sessions help the person make sense of the experience and apply insights to daily life.

Researchers think psychedelics may temporarily increase the brain's flexibility, making it easier to revisit difficult memories or rigid patterns of thinking with therapeutic support. The therapy is considered an essential part of the treatment, not an add-on.

What the Research Shows

Psilocybin

Clinical trials have found that psilocybin with psychological support can reduce symptoms of treatment-resistant depression and distress related to serious illness for some people. Larger and longer studies are still underway.

MDMA

Trials of MDMA-assisted therapy for PTSD showed encouraging results, but regulators have raised concerns about study design and safety data, and it is not approved for general use.

Ketamine and Esketamine

Ketamine can reduce depressive symptoms quickly for some people. Esketamine nasal spray is approved by Health Canada for treatment-resistant depression, and ketamine is sometimes used off-label in medical settings. Effects can be short-lived without ongoing treatment.

The Legal Situation in Canada

Psilocybin and MDMA are illegal outside of approved research or special access. Health Canada's Special Access Program allows physicians to request access to some restricted drugs for patients with serious conditions when other treatments have failed, and some people have received exemptions to use psilocybin in therapy. Unregulated retail sources do not have the same safeguards, and products may vary in strength or contain other substances.

Risks and Who Should Be Cautious

Psychological risks. Intense fear, distressing experiences, or worsening symptoms.
Psychosis and mania. People with a personal or family history of psychosis or bipolar disorder may be at higher risk, as described on the page about psychosis and schizophrenia.
Medical risks. Effects on heart rate and blood pressure, and interactions with medications such as some antidepressants.
Unsupervised use. Using psychedelics without screening and professional support carries greater risk.

What It Is Not

Psychedelic-assisted therapy is not a quick or guaranteed cure, and taking a psychedelic on your own is not the same as treatment. Established therapies remain the foundation of care for most people, as described on the pages about how depression is treated and how PTSD is treated. If you are considering any form of psychedelic treatment, talk with a physician or psychiatrist first. The page about treatment-resistant depression describes other options to explore.

Getting Support at Pacific Maple Psych Centre

If you are exploring options for depression, trauma, or other concerns, talking with a clinician can help you weigh which approaches fit your situation, both those widely available now and newer treatments as they become more accessible.

Pacific Maple Psych Centre offers a range of evidence-based therapies and psychological assessments, along with faster access to psychiatric consultation for clients of our practice, in Vancouver and virtually across BC. Our team can help you explore which options may be right for you.

Book a Session

Common Questions About Psychedelic-Assisted Therapy

How does psychedelic-assisted therapy differ from simply taking a psychedelic?

Psychedelic-assisted therapy combines a substance with screening, preparation, a supervised session, and integration therapy, which is very different from taking a psychedelic on your own.

Can I legally access psilocybin therapy in Canada?

Psilocybin is a controlled substance in Canada and is available for therapy only through clinical trials or special approval from Health Canada.

What have psilocybin trials found for treatment-resistant depression?

Early psilocybin trials suggest that, with psychological support, it can reduce treatment-resistant depression for some people, but research is still developing.

Is MDMA therapy approved for PTSD?

No. MDMA-assisted therapy for PTSD showed encouraging trial results, but it is not approved for general use.

Is ketamine approved for depression in Canada?

Esketamine nasal spray is approved by Health Canada for treatment-resistant depression, and ketamine is sometimes used off-label in medical settings.

What are the risks of psychedelic-assisted therapy?

Risks include distressing experiences, triggering psychosis or mania in vulnerable people, cardiovascular effects, and medication interactions.

Who should not try psychedelic therapy?

People with a personal or family history of psychosis or bipolar disorder, or certain heart conditions, may be at higher risk with psychedelic therapy.

What is integration in psychedelic therapy?

Integration is the follow-up therapy that helps people make sense of a psychedelic experience and apply insights to daily life.

Is microdosing the same as psychedelic-assisted therapy?

No. Microdosing involves small, repeated doses outside a structured therapy program, and research on its benefits is limited.

Should I talk to a doctor before trying psychedelic therapy?

Yes. Talk with a physician or psychiatrist before considering any psychedelic treatment to review risks, medications, and alternatives.